EcoDrugPlus

Bcl2 Like 10

Ensembl ID : ENSOMYG00000060575
Gene Symbol: BCL2L10
1 Cross references
125 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSOMYG00000047083
Gene Symbol: BCL2L10
1 Cross references
123 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSOMYG00000021602
Gene Symbol: BTK
1 Cross references
202 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOMYG00000012997
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOMYG00000020983
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOMYG00000041796
Gene Symbol: DNMT1
1 Cross references
204 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOMYG00000042427
Gene Symbol: DNMT1
1 Cross references
204 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOMYG00000055145
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSOMYG00000011026
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOMYG00000032934
Gene Symbol: TOP2B
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOMYG00000010443
Gene Symbol: TOP2B
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSOMYG00000016294
Gene Symbol: TOP1A
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).